- Home
- SF vs PCVX Comparison
SF vs PCVX Comparison
Compare SF & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SF | PCVX |
|---|---|---|
| Founded | 1890 | 2013 |
| Country | United States | United States |
| Employees | 9000 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 7.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SF | PCVX |
|---|---|---|
| Price | $77.47 | $55.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $90.33 | $88.25 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.58 | N/A |
| Revenue Next Year | $8.03 | N/A |
| P/E Ratio | $20.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $67.81 | $29.10 |
| 52 Week High | $134.74 | $65.00 |
Technical Indicators
Market Signals| Indicator | SF | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 50.88 |
| Support Level | $75.78 | $52.04 |
| Resistance Level | $79.12 | $56.04 |
| Average True Range (ATR) | 1.82 | 2.48 |
| MACD | 0.51 | -0.39 |
| Stochastic Oscillator | 81.22 | 13.23 |
Price Performance
Historical ComparisonAbout SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from trading and investment banking.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.